Fluoxetine HCl

别名: Lilly 110140 HCl, LY-110140 HCl 中文名称:盐酸氟西汀

Fluoxetine HCl是一种抗抑郁剂,选择性抑制5-羟色胺再摄取。

Fluoxetine HCl Chemical Structure

Fluoxetine HCl Chemical Structure

CAS: 56296-78-7

规格 价格 库存 购买数量
10mM (1mL in DMSO) 997 现货
10mg 794.43 现货
25mg 1217.77 现货
100mg 2446.52 现货
1g 8763.3 现货
更大包装 有超大折扣

400-668-6834

info@selleck.cn

免费分装
免费预溶

Fluoxetine HCl相关产品

相关信号通路图

细胞实验数据示例

细胞系 实验类型 给药浓度 孵育时间 活性描述 文献信息
HEK293 Function assay 30 mins Inhibition of human SERT expressed in HEK293 cells assessed as inhibition of serotonin reuptake after 30 mins by fluorescence assay, IC50=0.15μM 22938049
HEK293 Function assay 30 mins Inhibition of human NET expressed in HEK293 cells assessed as inhibition of noradrenaline reuptake after 30 mins by fluorescence assay, IC50=4.41μM 22938049
HEK293 Function assay 30 mins Inhibition of human DAT expressed in HEK293 cells assessed as inhibition of dopamine reuptake after 30 mins by fluorescence assay, IC50=18.4μM 22938049
BESM Antitrypanosomal assay 88 hrs Antitrypanosomal activity against Trypanosoma cruzi amastigotes infected in BESM cells measured after 88 hrs postinfection by HTS assay, EC50=7μM 20547819
BESM Cytotoxicity assay 88 hrs Cytotoxicity against BESM cells after 88 hrs by HTS assay, EC50=16μM 20547819
HEK293 Function assay 60 mins Displacement of [3H]Paroxetine from human recombinant SERT expressed in HEK293 cells after 60 mins, Ki=0.0014μM 23403082
HEK293 Function assay 60 mins Displacement of [3H]Paroxetine from human recombinant SERT expressed in HEK293 cells after 60 mins, IC50=0.0086μM 23403082
HEK293 Function assay 10 mins Inhibition of [3H]5-HT uptake at human SERT expressed in HEK293 cells preincubated for 10 mins prior to substrate addition measured after 4 mins by FLIPR assay, Ki=0.098μM 23602445
HEK293 Function assay 10 mins Inhibition of [3H]5-HT uptake at human SERT expressed in HEK293 cells preincubated for 10 mins prior to substrate addition measured after 4 mins by FLIPR assay, IC50=0.28184μM 23602445
HEK293 Function assay 10 mins Inhibition of [3H]norepinephrine uptake at human NET expressed in HEK293 cells preincubated for 10 mins prior to substrate addition measured after 4 mins by FLIPR assay, Ki=1.394μM 23602445
HEK293 Function assay 10 mins Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells preincubated for 10 mins prior to substrate addition measured after 4 mins by FLIPR assay, Ki=3.764μM 23602445
HEK293 Function assay 10 mins Inhibition of [3H]norepinephrine uptake at human NET expressed in HEK293 cells preincubated for 10 mins prior to substrate addition measured after 4 mins by FLIPR assay, IC50=6.30957μM 23602445
HEK293 Function assay 10 mins Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells preincubated for 10 mins prior to substrate addition measured after 4 mins by FLIPR assay, IC50=9.12011μM 23602445
HEK293 Function assay 15 mins Inhibition of serotonin reuptake at human SERT expressed in HEK293 cells after 15 mins by fluorescence neurotransmitter transporter assay, IC50=0.15μM 24974340
HEK293 Function assay 15 mins Inhibition of norepinephrine reuptake at human NET expressed in HEK293 cells after 15 mins by fluorescence neurotransmitter transporter assay, IC50=4.41μM 24974340
HEK293 Function assay 15 mins Inhibition of DA reuptake at human DAT expressed in HEK293 cells after 15 mins by fluorescence neurotransmitter transporter assay, IC50=18.4μM 24974340
HEK293 Function assay 15 mins Inhibition of human SERT expressed in HEK293 cells at incubated for 15 mins by neurotransmitter reuptake assay, IC50=0.15μM 25221656
HEK293 Function assay 15 mins Inhibition of human NET expressed in HEK293 cells at incubated for 15 mins by neurotransmitter reuptake assay, IC50=4.41μM 25221656
HEK293 Function assay 15 mins Inhibition of human DAT expressed in HEK293 cells at incubated for 15 mins by neurotransmitter reuptake assay, IC50=18.4μM 25221656
RD Antiviral assay 5 mins Antiviral activity against Enterovirus D68 US/KY/14-18953 infected in human RD cells assessed as inhibition of virus-induced cytopathic effect incubated for 5 mins under shaking condition and measured after 3 days by neutral red dye-based photometric meth, EC50=1μM 30912944
RD Cytotoxicity assay 3 days Cytotoxicity against human RD cells after 3 days by neutral red dye-based photometric method, CC50=11.9μM 30912944
mammalian cells Function assay Inhibition of human Potassium channel HERG expressed in mammalian cells, IC50=1.51356μM 12873512
JAR Function assay Inhibition concentration against [3H]5-HT uptake by human serotonin transporter in JAR cells, IC50=0.0324μM 15239661
K562 Cytotoxicity assay Cytotoxicity to reduce chronic myeloid leukemia K 562 cells, CC50=25μM 15267229
U937 Cytotoxicity assay Cytotoxicity to reduce human histolytic lymphoma U937 cells, CC50=33.3μM 15267229
HEK293 Function assay Inhibition of [3H]5-HT uptake at 5HT transporter expressed in HEK293 cells, IC50=0.016μM 16750359
HEK293 Function assay Inhibition of DA transporter expressed in HEK293 cells, IC50=4.4μM 16750359
HEK293 Function assay Inhibition of [3H]NA uptake at NA transporter expressed in HEK293 cells, IC50=5.2μM 16750359
HEK293 Function assay Inhibition of [3H]5-HT reuptake at 5HT transporter in HEK293 cells, IC50=0.016μM 16750363
HEK293 Function assay Inhibition of [3H]DA reuptake at DA transporter in HEK293 cells, IC50=4.4μM 16750363
HEK293 Function assay Inhibition of [3H]NA reuptake at NA transporter in HEK293 cells, IC50=5.2μM 16750363
Jar Function assay Inhibition of [3H]5-HT uptake at human 5-HT transporter expressed in Jar cells, IC50=0.0394μM 16854086
SK-N-MC Function assay Displacement of N-[3H]alpha-methylhistamine from human histamine H3 receptor expressed in SK-N-MC cells, Ki=7.3μM 17307358
CHO Function assay Inhibition of human ERG expressed in CHO cells by whole cell patch clamp technique, IC50=1.51356μM 18448342
HEK293 Function assay Inhibition of serotonin uptake at human SERT in human HEK293 cells, IC50=0.047μM 18550369
HEK293 Function assay Inhibition of norepinephrine uptake at human NET in human HEK293 cells, IC50=2μM 18550369
HEK293 Function assay Inhibition of dopamine uptake at human DAT in human HEK293 cells, IC50=6μM 18550369
JAR Function assay Inhibition of 5HT uptake at human SERT expressed in human JAR cells, IC50=0.0094μM 18557608
HEK Function assay Inhibition of serotonin uptake at human SERT expressed in HEK cells, IC50=0.047μM 18667309
HEK Function assay Inhibition of norepinephrine uptake at human NET expressed in HEK cells, IC50=2μM 18667309
HEK Function assay Inhibition of dopamine uptake at human DAT expressed in HEK cells, IC50=6μM 18667309
JAR Function assay Inhibition of serotonin uptake at human SERT expressed in JAR cells, IC50=0.01μM 18771916
MDCK Function assay Inhibition of norepinephrine uptake at human NET expressed in MDCK cells, IC50=0.563μM 18771916
Jar Function assay Inhibition of 5-HT transporter-mediated [3H]5HT uptake in human Jar cells, IC50=0.0394μM 18834188
JAR Function assay Inhibition of serotonin uptake at human SERT expressed in JAR cells, IC50=0.0094μM 18951020
HEK293 Function assay Displacement of [125I]RTI55 from human recombinant SERT expressed in HEK293 cells, Ki=0.0011μM 19014888
HEK293 Function assay Inhibition of [3H]5HT from human recombinant SERT expressed in HEK293 cells, IC50=0.007μM 19014888
HEK293 Function assay Inhibition of [3H]NE from human recombinant NET expressed in HEK293 cells, IC50=1.02μM 19014888
HEK293 Function assay Displacement of [125I]RTI55 from human recombinant NET expressed in HEK293 cells, Ki=1.56μM 19014888
HEK293 Function assay Displacement of [125I]RTI55 from human recombinant DAT expressed in HEK293 cells, Ki=6.67μM 19014888
HEK293 Function assay Inhibition of [3H]DA from human recombinant DAT expressed in HEK293 cells, IC50=19.5μM 19014888
HEK293 Function assay Displacement of [125I]RTI-55 from human recombinant SERT expressed in HEK293 cells by scintillation counting, Ki=0.0011μM 19256502
HEK293 Function assay Displacement of [3H]serotonin from human recombinant SERT expressed in HEK293 cells by scintillation counting, IC50=0.0073μM 19256502
HEK293 Function assay Displacement of [3H]norepinephrine from human recombinant NET expressed in HEK293 cells by scintillation counting, IC50=1.02μM 19256502
HEK293 Function assay Displacement of [125I]RTI-55 from human recombinant NET expressed in HEK293 cells by scintillation counting, Ki=1.56μM 19256502
HEK293 Function assay Displacement of [125I]RTI-55 from human recombinant DAT expressed in HEK293 cells by scintillation counting, Ki=6.67μM 19256502
HEK293 Function assay Displacement of [3H]dopamine from human recombinant DAT expressed in HEK293 cells by scintillation counting, IC50=19.5μM 19256502
JAR Function assay Inhibition of serotonin uptake at human SERT expressed in human JAR cells, IC50=0.01μM 19329313
MDCK-Net6 Function assay Inhibition of norepinephrine uptake at human NET expressed in MDCK-Net6 cells, IC50=0.563μM 19329313
JAR Function assay Inhibition of serotonin uptake at human SERT expressed in JAR cells, IC50=0.0094μM 19632110
JAR Function assay Inhibition of human SERT expressed in JAR cells, IC50=0.0094μM 19713106
JAR Function assay Inhibition of [3H]hydroxytryptamine creatinine sulfate uptake at human SERT expressed in human JAR cells, IC50=0.0094μM 19722525
HEK293 Function assay Displacement of [I125]RTI-55 from human SERT transfected in human HEK293 cells, IC50=0.0025μM 20034793
JAR Function assay Inhibition of serotonin uptake at human SERT expressed in human JAR cells, IC50=0.0094μM 20131864
JAR Function assay Inhibition of human SERT expressed in human JAR cells, IC50=0.0094μM 20378347
JAR Function assay Inhibition of SERT-mediated serotonin uptake in human JAR cells, IC50=0.0094μM 20462211
HEK293 Function assay Displacement of [3H] astemizole from human recombinant ERG channel expressed in HEK293 cells, IC50=3.1μM 20637635
HEK293 Function assay Inhibition of serotonin reuptake at human SERT expressed in HEK293 cells, IC50=0.0031μM 20724153
HEK293 Function assay Inhibition of [3H]serotonin reuptake at human SERT expressed in HEK293 cells by scintillation counting, IC50=0.0052μM 21093273
LLC-PK1 Function assay Inhibition of [3H]serotonin reuptake at human recombinant SERT expressed in LLC-PK1 cells by liquid scintillation counting, IC50=0.005012μM 21310612
HEK293 Function assay Inhibition of serotonin reuptake at SERT expressed in HEK293 cells, IC50=0.005012μM 21739935
JAR Function assay Inhibition of human SERT expressed in JAR cells assessed as serotonin uptake, IC50=0.0094μM 21916421
HEK293 Function assay Inhibition of human SERT-mediated serotonin reuptake in HEK293 cells, EC50=0.0027μM 21927645
CHO Function assay Inhibition of rat voltage-gated K channel 3.1 expressed in CHO cells by patch clamp assay, IC50=13.1μM 23121096
HEK293 Function assay Displacement of [3H]imipramin from human recombinant SERT over-expressed in HEK293 cells, IC50=0.0072μM 24012181
HEK293 Function assay Inhibition of of human TREK1 expressed in HEK293 cells assessed as reduction in channel currents, IC50=14μM 26588045
tsA201 Function assay Inhibition of of human TREK1 expressed in tsA201 cells assessed as reduction in channel currents, IC50=19μM 26588045
OHS-50 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells 29435139
MG 63 (6-TG R) qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells 29435139
Huh7 Antiviral assay Antiviral activity against DENV2 infected in human Huh7 cells by qRT-PCR analysis, IC50=0.38μM 31128447
点击查看更多细胞系数据

生物活性

产品描述 Fluoxetine HCl是一种抗抑郁剂,选择性抑制5-羟色胺再摄取。
靶点
5-HT [1]
体外研究(In Vitro)
体外研究活性

Fluoxetine阻断细胞增殖的下调,导致海马细胞的不可避免的冲击(IS)。[1]

Fluoxetine增加成年大鼠的海马的齿状回的新生细胞的数量。Fluoxetine也增加了前度皮质的增殖细胞的数目。[2]

Fluoxetine加速未成熟神经元的成熟。Fluoxetine增强海马齿状回的神经依赖的长时程增强(LTP)。[3]

Fluoxetine而不是Citalopram, Fluvoxamine, Paroxetine和Sertraline,增加前额叶皮层中去甲肾上腺素和多巴胺的细胞外水平。在急性全身给药后,Doxazosin产生强劲而持续增加的去甲肾上腺素和多巴胺的胞外浓度。[4]

体内研究(In Vivo)
体内研究活性

在动物成年雄性SD大鼠中,Fluoxetine扭转不可避免的冲击导致的逃避潜伏期。[1]

在动物成年雄性SD大鼠中,Fluoxetine和Olanzapine联用产生稳健,持续的细胞外多巴胺水平([DA](前))和去甲肾上腺素([东北](前))的增加,超过基准达361%和272%,这是显著大于两种药物单独使用。[5]

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT05634707 Recruiting
Primary Brain Tumor|Brain Tumor Recurrent
Duke University
August 5 2023 Early Phase 1
NCT04676139 Unknown status
Nocturnal Enuresis
Mansoura University
July 1 2020 Phase 3
NCT01615055 Withdrawn
Cognitive Dysfunction
University of California Los Angeles|City of Hope Medical Center
June 2018 Early Phase 1
NCT03390933 Completed
Depression|Hemodialysis-Induced Symptom
MetroHealth Medical Center
March 1 2018 Phase 4

化学信息&溶解度

分子量 345.79 分子式

C17H18F3NO.HCl

CAS号 56296-78-7 SDF Download Fluoxetine HCl SDF
Smiles CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F.Cl
储存条件(自收到货起)

体外溶解度
批次:

DMSO : 69 mg/mL ( (199.54 mM) ;DMSO吸湿会降低化合物溶解度,请使用新开封DMSO)

Ethanol : 69 mg/mL (199.54 mM)

Water : 4 mg/mL (11.56 mM)

摩尔浓度计算器

体内溶解度
批次:

现配现用,请按从左到右的顺序依次添加,澄清后再加入下一溶剂

动物体内配方计算器

实验计算

摩尔浓度计算器

质量 浓度 体积 分子量

动物体内配方计算器(澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)

mg/kg g μL

第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)

% DMSO % % Tween 80 % ddH2O
%DMSO %

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于μL DMSO溶液(母液浓度mg/mL,:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);

体内配方配制方法:μL DMSO母液,加入μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入μL ddH2O,混匀澄清。

体内配方配制方法:μL DMSO母液,加入μL Corn oil,混匀澄清。

注意:1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

* 必填项

请输入您的姓名
请输入您的邮箱地址 请输入一个有效的邮箱地址
请写点东西给我们
Tags: buy Fluoxetine HCl | Fluoxetine HCl supplier | purchase Fluoxetine HCl | Fluoxetine HCl cost | Fluoxetine HCl manufacturer | order Fluoxetine HCl | Fluoxetine HCl distributor
在线咨询
联系我们